NASDAQ:GLTO

Galecto Stock Insider Trading

Healthcare > Biotechnology

Buy GLTO

*Your capital is at risk

$22.20

+0 (+0%)

At Close: Jun 23, 2026

Galecto Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.92. In total, the insiders bought 30.6M and sold 7.52K GLTO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.92
● Buy	30.6M shares
● Sell	7.52K shares
85% Buy Activity Negligible or No Correlation
Buy Signal High Confidence Nov 10, 2025 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 99.92. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (85% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 09, 2026 Buy	Series C Preferred Stock M-Exempt	Fairmount Funds Management Llc	Director	2 904 Value: $69.7K
Feb 09, 2026 Buy	Common Stock M-Exempt	Bruno Julianne Director	Director	129 000 Value: $3.10M
Feb 09, 2026 Buy	Common Stock M-Exempt	Fairmount Funds Management Llc	Director	2 904 000 Value: $69.7M
Feb 09, 2026 Buy	Series C Preferred Stock M-Exempt	Fairmount Funds Management Llc	Director	5 809 Value: $139.4K
Feb 09, 2026 Buy	Series C Preferred Stock M-Exempt	Bruno Julianne Director	Director	129 Value: $3K
Feb 09, 2026 Buy	Common Stock M-Exempt	Fairmount Funds Management Llc	Director	5 809 000 Value: $0.14B
Jan 05, 2026 Buy	Common Stock J-Other	Sattarzadeh Sherwin Insider	Other	0 Value: $0
Jan 05, 2026 Buy	Common Stock A-Award	Sattarzadeh Sherwin Chief Operating Officer	C-Suite Officer	190 376 Value: $4.05M
Jan 05, 2026 Buy	Stock Option (right to buy) A-Award	Sattarzadeh Sherwin Chief Operating Officer	C-Suite Officer	444 209 Value: $9.69M
Jan 05, 2026 Buy	Common Stock J-Other	Hewes L. Becker Insider	Other	0 Value: $0
Jan 05, 2026 Buy	Stock Option (right to buy) A-Award	Hewes L. Becker Chief Medical Officer	Officer	528 603 Value: $11.5M
Jan 05, 2026 Buy	Common Stock A-Award	Hewes L. Becker Chief Medical Officer	Officer	264 629 Value: $5.63M
Jan 02, 2026 Buy	Restricted Stock Units M-Exempt	Winslow Garrett General Counsel	Officer	680 Value: $14.5K
Jan 02, 2026 Sell	Common Stock S-Sale	Winslow Garrett General Counsel	Officer	255 Value: $5K
Jan 02, 2026 Buy	Common Stock M-Exempt	Winslow Garrett General Counsel	Officer	680 Value: $14.5K
Jan 02, 2026 Buy	Common Stock M-Exempt	Schambye Hans T. Chief Executive Officer	CEO / President	1 360 Value: $29.0K
Jan 02, 2026 Sell	Common Stock S-Sale	Schambye Hans T. Chief Executive Officer	CEO / President	700 Value: $15.0K
Jan 02, 2026 Buy	Restricted Stock Units M-Exempt	Schambye Hans T. Chief Executive Officer	CEO / President	1 360 Value: $29.0K
Jan 02, 2026 Buy	Common Stock M-Exempt	Firmani Lori Chief Financial Officer	C-Suite Officer	374 Value: $8K
Jan 02, 2026 Sell	Common Stock S-Sale	Firmani Lori Chief Financial Officer	C-Suite Officer	135 Value: $3K
Jan 02, 2026 Buy	Restricted Stock Units M-Exempt	Firmani Lori Chief Financial Officer	C-Suite Officer	374 Value: $8K
Nov 10, 2025 Buy	Series C Preferred Stock	Bruno Julianne Director	Director	129 000 Value: $2.20M
Nov 10, 2025 Buy	Common Stock	Bruno Julianne Director	Director	0 Value: $0
Nov 10, 2025 Buy	Common Stock J-Other	Cain Christopher W. Insider	Other	0 Value: $0
Nov 10, 2025 Buy	Series B Preferred Stock	Fairmount Funds Management Llc	Director	16 366 000 Value: $0.28B

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT GALECTO, INC.

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a ...

Read Full Profile Here